MentionFox
Home › Executive changes › Tarsus Pharmaceuticals, Inc.
Leadership changes · TARS · SEC Form 8-K, Item 5.02

Leadership changes at Tarsus Pharmaceuticals, Inc. (2026)

Before you join, sell to or invest in Tarsus Pharmaceuticals, Inc.

MentionFox check on Tarsus Pharmaceuticals, Inc.: only 2 sources on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/tarsus-pharmaceuticals

Check Tarsus Pharmaceuticals, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Tarsus Pharmaceuticals, Inc.?

Who joined and who left Tarsus Pharmaceuticals, Inc. (TARS)? 2 filings reported from 2026-02-18 to 2026-07-13, each cited to the company's own filing.

As of November 14, 2026, Tarsus Pharmaceuticals, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from February 18, 2026 to July 13, 2026 (Form 8-K, July 13, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Jennison Associates LLC also filed stake reports on 14 other companies ↓

Sell to companies like Tarsus Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes2
Latest filing2026-07-13

Tarsus Pharmaceuticals, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-02-18 to 2026-07-13. Every row below is cited to the filing it comes from, and this page adds each new change as Tarsus Pharmaceuticals, Inc. files it.

Also on the record for Tarsus Pharmaceuticals, Inc.

DateRecordFigureOur pageSource
November 5, 2026Stake report, Schedule 13G, by FMR LLC6.4% of the class5%+ stakesSource
September 4, 2026Acquired Alkeus Pharmaceuticals, Inc.$270MAcquisitionSource
August 13, 2026Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP Ltd.6.5% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G, by JANUS HENDERSON GROUP PLC5.3% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G/A, by Deep Track Capital, LP8.46% of the class5%+ stakesSource
May 8, 2026Stake report, Schedule 13G/A, by PRUDENTIAL FINANCIAL INC4.3% of the class5%+ stakesSource
May 6, 2026Stake report, Schedule 13G/A, by Jennison Associates LLC4% of the class5%+ stakesSource
March 27, 2026Stake report, Schedule 13G/A, by The Vanguard Group—5%+ stakesSource
February 17, 2026Stake report, Schedule 13G/A, by TANG CAPITAL MANAGEMENT, LLC2.8% of the class5%+ stakesSource
November 14, 2025Stake report, Schedule 13G/A, by Deep Track Capital, LP7.11% of the class5%+ stakesSource
August 14, 2025Stake report, Schedule 13G/A, by RTW Investments, LP8.1% of the class5%+ stakesSource
July 28, 2025Stake report, Schedule 13G, by Deep Track Capital, LP5.6% of the class5%+ stakesSource

Selling to them or working with them? See who runs Tarsus Pharmaceuticals, Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on Tarsus Pharmaceuticals, Inc. and the records around it.

Tarsus Pharmaceuticals, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Tarsus Pharmaceuticals, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Tarsus Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Tarsus Pharmaceuticals, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    14 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-07-13Reportednot named in the filing8-K, 2026-07-13
2026-02-18Reportednot named in the filing8-K, 2026-02-18
Selling to Tarsus Pharmaceuticals, Inc.?

New leaders reset buying decisions — get the Full Report on Tarsus Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Tarsus Pharmaceuticals, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the senior executive at Tarsus Pharmaceuticals, Inc., with the record behind each one.

Find candidates like senior executive at Tarsus Pharmaceuticals, Inc.

Every change, in the filing's words

Filed 2026-07-13 · 8-K

Reported

On July 13, 2026, Tarsus Pharmaceuticals, Inc. (the "Company") announced that Aziz Mottiwala would be leaving his role as the Company's Chief Commercial Officer and leaving his employment with the Company on July 15, 2026, to pursue a new opportunity as Chief Executive Officer of a public medical device company.
Filed 2026-02-18 · 8-K

Reported

On February 18, 2026, the Board of Directors (the "Board") of Tarsus Pharmaceuticals, Inc. (the "Company"), upon the recommendation of its Nominating and Corporate Governance Committee (the "Nominating Committee"), expanded the size of the Board from seven to eight directors and appointed David E.I. Pyott to the Board, effective immediately.

Also stated in this filing

  • Mr. Pyott will serve as a Class III director with a term expiring at the Company's 2026 annual meeting of stockholders or until his successor is duly elected and qualified.
  • Further, effective immediately, the Board appointed Mr. Pyott to serve as Chairperson of the Commercial Committee of the Board and as member of the Nominating Committee as well as the Compensation Committee of the Board.
  • The Board has determined that Mr. Pyott is independent under the listing standards of the Nasdaq Stock Market and the rules and regulations of the Securities and Exchange Commission (the "SEC").
  • As a non-employee director, Mr. Pyott will receive cash and equity compensation paid by the Company pursuant to its non-employee director compensation policy, as amended, which includes an initial grant with a target grant value of $540,000, with 50% of the award granted as an option to purchase shares of the Company's common stock and 50% of the award granted as RSUs.

Tools for this story

Each opens in a new tab, filled in for Tarsus Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/tarsus-pharmaceuticals
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
What changed at the top of Tarsus Pharmaceuticals, Inc.?. MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/tarsus-pharmaceuticals